Currently, there are 65.52M common shares owned by the public and among those 54.86M shares have been available to trade.
The company’s stock has a 5-day price change of 26.88% and -35.48% over the past three months. LYRA shares are trading -42.83% year to date (YTD), with the 12-month market performance down to -97.72% lower. It has a 12-month low price of $0.08 and touched a high of $5.65 over the same period. LYRA has an average intraday trading volume of 1.20 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 16.22%, -20.56%, and -46.22% respectively.
Institutional ownership of Lyra Therapeutics Inc (NASDAQ: LYRA) shares accounts for 37.92% of the company’s 65.52M shares outstanding.
It has a market capitalization of $7.78M and a beta (3y monthly) value of 0.08. The earnings-per-share (ttm) stands at -$1.44. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.48% over the week and 16.53% over the month.
Earnings per share for the fiscal year are expected to increase by 42.42%, and -2.02% over the next financial year. EPS should grow at an annualized rate of 21.95% over the next five years, compared to -2.22% over the past 5-year period.
Looking at the support for the LYRA, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on May 07, 2024, with the firm’s price target at $10-$0.50. H.C. Wainwright coverage for the Lyra Therapeutics Inc (LYRA) stock in a research note released on May 07, 2024 offered a Neutral rating with a price target of $2. BTIG Research on their part issued Buy rating on October 06, 2023.
